Full Press Release Details
Oncolytics Biotech Inc. Announces Formation of Science and
Technology Committee
CALGARY, April 29, 2016 /CNW/ - Oncolytics Biotech
Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) ("Oncolytics" or the "Company") today announced the formation of
a Science and Technology Committee made up of directors Dr. William Rice and Dr. Bernd Seizinger.
"In addition to many years of senior
leadership in oncology drug development, Drs. Rice and Seizinger bring strong scientific and medical credentials along with a wealth
of industry and academic contacts to their roles on the committee," said Wayne Pisano, Chairman of Oncolytics. "Cancer
research and drug development, and indeed our own specific understanding of how REOLYSIN works, continue to evolve
at a rapid pace. The committee is charged with supporting REOLYSIN 's further development in the context of the
broader oncology space with an ultimate focus on reaching a commercial endpoint."
Dr. William Rice has held the position
of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. Preceding Aptose, he served as
Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief
Executive Officer and Director of Achillion Pharmaceuticals, Inc. He has also served as Senior Scientist and Head of the Drug Mechanism
Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center, and as a faculty member in the Division
of Pediatric Hematology and Oncology at Emory School of Medicine. Dr. Rice holds a PhD in biochemistry from Emory University and
was a post-doctoral trainee in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Michigan
Bernd Seizinger, MD, PhD, has held the
position of Chairman/Executive Chairman of Opsona Therapeutics Ltd. since 2009. From 1998 to 2009, he served as President and Chief
Executive Officer of GPC Biotech. He also served as Vice President of Oncology Drug Discovery and, in parallel, Vice President
of Corporate and Academic Alliances at Bristol-Myers Squibb. Prior to his appointments in the biotechnology and pharmaceuticals
sectors, Dr. Seizinger held professorships and senior staff appointments at Harvard Medical School, Princeton University and Massachusetts
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN ,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking
statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the role of the Science
and Technology Committee, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve
known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue
research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN
outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully
commercialize REOLYSIN , uncertainties related to the research, development and manufacturing of pharmaceuticals,
changes in technology, general changes to the economic environment and uncertainties related to the regulatory process. Investors
should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking statements. Investors should consider statements that include the words
"believes", "expects", "anticipates", "intends", "estimates", "plans",
"projects", "should", or other expressions that are predictions of or indicate future events or trends, to
be uncertain and forward-looking. Investors are cautioned against placing undue reliance on forward-looking statements. The Company
does not undertake to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
For further information: NATIONAL Equicom, Nick Hurst, 800
6th Ave. SW, Suite 1600, Calgary, Alberta T2P 3G3, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@national.ca; NATIONAL Equicom,
Michael Moore, San Diego, CA, Tel: 858.886.7813, mmoore@national.ca; Dian Griesel, Inc., Susan Forman, 335 West 38th Street, 3rd
Floor, New York, NY 10018, Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 06:30e 29-APR-16